AR121802A1 - ANTI-CD98 ANTIBODIES AND THEIR USES - Google Patents

ANTI-CD98 ANTIBODIES AND THEIR USES

Info

Publication number
AR121802A1
AR121802A1 ARP210100937A ARP210100937A AR121802A1 AR 121802 A1 AR121802 A1 AR 121802A1 AR P210100937 A ARP210100937 A AR P210100937A AR P210100937 A ARP210100937 A AR P210100937A AR 121802 A1 AR121802 A1 AR 121802A1
Authority
AR
Argentina
Prior art keywords
antigen
antibodies
conjugates
diagnostic
antibody
Prior art date
Application number
ARP210100937A
Other languages
Spanish (es)
Inventor
Suzanne Edavettal
Sanjaya Singh
Derrick Domingo
Deepti Wilkinson
Pilar Cejudo-Martin
Pharavee Jaisprasart
Brian Geist
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR121802A1 publication Critical patent/AR121802A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos anti-CD98 monoclonales y fragmentos de unión al antígeno de estos para suministrar un agente al cerebro de un sujeto que lo necesita. También se describen conjugados y construcciones de fusión que contienen el anticuerpo anti-CD98 o fragmento de unión al antígeno de este acoplado a un agente terapéutico o de diagnóstico, tal como un segundo anticuerpo y fragmento de unión al antígeno de este, para tratar o detectar un trastorno neurológico y/o suministrar un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica. También se describen ácidos nucleicos que codifican los anticuerpos, conjugados y constructos de fusión y células huésped recombinantes relacionadas.Monoclonal anti-CD98 antibodies and antigen-binding fragments thereof for delivering an agent to the brain of a subject in need thereof are disclosed. Also described are conjugates and fusion constructs containing the anti-CD98 antibody or antigen-binding fragment thereof coupled to a diagnostic or therapeutic agent, such as a second antibody and antigen-binding fragment thereof, for treating or detecting a neurological disorder and/or deliver a diagnostic or therapeutic agent across the blood-brain barrier. Nucleic acids encoding the antibodies, conjugates and fusion constructs, and related recombinant host cells are also disclosed.

ARP210100937A 2020-04-08 2021-04-08 ANTI-CD98 ANTIBODIES AND THEIR USES AR121802A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063006988P 2020-04-08 2020-04-08

Publications (1)

Publication Number Publication Date
AR121802A1 true AR121802A1 (en) 2022-07-13

Family

ID=83218598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100937A AR121802A1 (en) 2020-04-08 2021-04-08 ANTI-CD98 ANTIBODIES AND THEIR USES

Country Status (1)

Country Link
AR (1) AR121802A1 (en)

Similar Documents

Publication Publication Date Title
AR127521A2 (en) COMPOSITIONS AND METHODS FOR SUPPLY TO THE BLOOD-BRAIN BARRIER
AR127518A2 (en) ANTI-CD98 ANTIBODIES AND USES OF THESE
ES2819451T3 (en) High Affinity PD-1 Agents and Procedures for Use
BR112015010046A2 (en) ANTIGEN-BINDING PROTEINS OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND THEIR METHOD OF PRODUCTION, VECTOR, TRANSGENIC MICROORGANISM HOST CELL, IMMUNOCONJUGATE AND THEIR USE, PHARMACEUTICAL COMPOSITION AND MURINE HYBRIDOMA
Monnier et al. In vivo applications of single chain Fv (variable domain)(scFv) fragments
Friedrich et al. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety
ES2758533T3 (en) Diagnostic use of antibodies against ROR1 protein
CO2021006092A2 (en) Il-15 / il-15ralpha-fc fusion proteins targeting pd-1 and uses thereof in combination therapies
BR112014010383A2 (en) antigen-binding protein and use as antigen-binding product for cancer treatment
PE20211284A1 (en) ANTI-NKG2A ANTIBODIES AND USES OF THEM
CO6351751A2 (en) HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
RU2018139811A (en) MULTI-SPECIFIC ANTI-BINDING CONSTRUCTIONS TARGETING IMMUNOTHERAPEUTIC MEANS
CR9236A (en) MOLECULAS OF UNION TO THE ANTIGEN THAT FIX EGER, VECTORS THAT CODE THEM AND USES OF THE SAME
KR20110119631A (en) Sparc binding peptides and uses thereof
BR112019004711A2 (en) chimeric antigen receptors comprising bcma specific type III fibronectin domains and uses thereof
JP2015532102A5 (en)
CA2874422C (en) Anti-cd26 antibodies and uses thereof
AR124455A2 (en) SPECIFIC BINDING PROTEINS AND THEIR USES
AR121802A1 (en) ANTI-CD98 ANTIBODIES AND THEIR USES
Zhou et al. DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration
Dela Cruz Chuh et al. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response
AR121803A1 (en) COMPOSITIONS AND METHODS FOR DELIVERY TO THE BLOOD-BRAIN BARRIER
PE20070500A1 (en) TREATMENT OF DISEASES USING AN IMPROVED SYSTEM OF REGULATED EXPRESSION
BR112021017046A2 (en) Humanized antifolate receptor 1 chimeric antigen receptors and their uses
MX2020003806A (en) Dna monoclonal antibodies targeting ctla-4 for the treatment and prevention of cancer.